Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Kyprolis
(United States) [Available]Synonyms :
carfilzomib
Class :
Proteasome Inhibitors, Antineoplastics
Brand Name :
Kyprolis
(United States) [Available]Synonyms :
carfilzomib
Class :
Proteasome Inhibitors, Antineoplastics
Dosage Forms & Strengths
Intravenous injection
10mg
30mg
60mg
Safety and efficacy not established
refer adult dosing
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
carfilzomib: they may increase the thrombogenic effect of hormonal contraceptives
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
it may decrease the serum concentration of Estrogen Derivatives
bazedoxifene/conjugated estrogens
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
it may decrease the serum concentration of Estrogen Derivatives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
protease inhibitors may reduce the level of serum concentration of hormonal contraceptives
When carfilzomib is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
when both drugs are combined, there may be an increased level of serum concentration of etoposide   
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in a high level of serum concentration  
when both drugs are combined, there may be an increased risk of nerve damage   
may enhance the risk or severity of adverse effects when combined with carfilzomib
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration of estrogen derivatives
combining piperine with carfilzomib may result in an increased serum concentration of carfilzomib
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
may enhances the effects of the other by pharmacodynamic synergism
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
it decreases the effect of thrombogenesis of carfilzomib
Frequency defined
>10%
Nausea (44.9%)
Anemia (46.8%)
Thrombocytopenia (36.3%)
Diarrhea (32.7%)
Dyspnea (34.6%)
Pyrexia (30.4%)
Headache (27.6%)
Upper respiratory tract infection (28.3%)
Cough (26%)
Fatigue (55.5%)
Lymphopenia (24%)
Increase in blood creatinine (24.1%)
Peripheral Edema (24%)
Constipation (20.9%)
Vomiting (22.2%)
Neutropenia (20.7%)
Insomnia (17.9%)
Back pain (20.2%)
Chills (16%)
Muscle spasms (14.4%)
Arthralgia (15.8%)
Pregnancy consideration:
AU pregnancy category: C
US FDA pregnancy category: Not assigned.
Breastfeeding warnings:
Excreted into human milk is Unknown
Pregnancy category:
Category A:Â well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D:Â adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Patient information leaflet
Generic Name: carfilzomib
Why do we use carfilzomib?
carfilzomib is a medication used to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It belongs to a class of drugs called proteasome inhibitors. carfilzomib works by inhibiting the activity of proteasomes, which are responsible for breaking down proteins in cells. By blocking proteasomes, carfilzomib can lead to the accumulation of proteins within cancer cells, ultimately causing their death. carfilzomib is typically used when other treatments have not been effective or have stopped working.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
